Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
BioSpace13h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Hosted on MSN13h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
AllAfrica.com20h
South Africa: Which of the Breakthrough Weight Loss Medicines Can You Get in SA?
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...
MoneySense5h
Stock market news for Canadian investors: Eli Lilly, BCE and more
Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the details for Canadian investors.
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.